-
Product Insights
NewNet Present Value Model: Marker Therapeutics Inc’s Zelenoleucel
Empower your strategies with our Net Present Value Model: Marker Therapeutics Inc's Zelenoleucel report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewInnovations in Inflammatory Disease Markers – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Inflammatory Disease Markers - Global Pipeline Summary" provides comprehensive information about the Inflammatory Disease Markers pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Inflammatory Disease Markers report provides key information and data related to: Extensive coverage of the Inflammatory Disease Markers under development Review details of major pipeline products which include product description, licensing and collaboration details and other developmental...
-
Product Insights
NewInnovations in Cardiac Marker Tests – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Cardiac Marker Tests - Global Pipeline Summary" provides comprehensive information about the Cardiac Marker Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Cardiac Marker Tests report provides key information and data related to: Extensive coverage of the Cardiac Marker Tests under development Review details of major pipeline products which include product description, licensing and collaboration details and other developmental...
-
Product Insights
NewInnovations in Cardiac Markers Rapid Tests & POC – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Cardiac Markers Rapid Tests & POC - Global Pipeline Summary" provides comprehensive information about the Cardiac Markers Rapid Tests & POC pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Cardiac Markers Rapid Tests & POC report provides key information and data related to: Extensive coverage of the Cardiac Markers Rapid Tests & POC under development Review details of major...
-
Product Insights
NewInnovations in Other Cardiac Marker Point of Care (POC) Tests – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Other Cardiac Marker Point of Care (POC) Tests - Global Pipeline Summary" provides comprehensive information about the Other Cardiac Marker Point of Care (POC) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Other Cardiac Marker Point of Care (POC) Tests report provides key information and data related to: Extensive coverage of the Other Cardiac Marker Point of...
-
Product Insights
Cardiac Markers Rapid Tests and POC Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Cardiac Markers Rapid Tests and POC Pipeline Market Report Overview Cardiac markers rapid tests & point of care (POC) are simple to perform rapid diagnostic tests that are ready to use, accurate, economical, and for infield use. These tests are suggested for individuals suspected of any indication. The Cardiac Markers Rapid Tests and POC pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XSTEM in Osteoarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XSTEM in Osteoarthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XSTEM in Osteoarthritis Drug Details: XSTEM is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFV-890 in Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Coronary Artery Disease (CAD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFV-890 in Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Inflammation Drug Details: DFV-890 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFV-890 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Familial Cold Autoinflammatory Syndrome...